Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Bought by Coastal Bridge Advisors LLC

Coastal Bridge Advisors LLC boosted its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 1,609.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 276,817 shares of the company's stock after purchasing an additional 260,627 shares during the quarter. Coastal Bridge Advisors LLC owned approximately 0.48% of Ginkgo Bioworks worth $2,718,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in Ginkgo Bioworks in the 4th quarter valued at approximately $29,000. KBC Group NV purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at $46,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at $116,000. Finally, Palumbo Wealth Management LLC purchased a new stake in Ginkgo Bioworks during the 4th quarter worth about $144,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 1.5 %

Shares of Ginkgo Bioworks stock traded down $0.12 during mid-day trading on Friday, hitting $7.75. 1,025,844 shares of the stock were exchanged, compared to its average volume of 1,473,866. The stock has a market capitalization of $449.76 million, a price-to-earnings ratio of -0.59 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $38.58. The company has a 50-day simple moving average of $7.13 and a 200 day simple moving average of $9.07.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The firm had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. Equities research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.